Orderly Market Agreement - Director’s Dealing

By in

                                                                                                                                                                                     25 June 2018

Sativa Investments PLC

 (“Sativa” or the “Company”)

Orderly Market Agreement – Director’s Dealing

Sativa Investments PLC (NEX:SATI), the UK’s first medicinal cannabis investment vehicle, announces that today, 25 June 2018, Mark Blower, an executive director of the Company, sold 1,000,000 ordinary shares of £0.0025 at a price of £0.04 per share and Noel Lyons, a non-executive Director of the Company, sold 500,000 ordinary shares of £0.0025 each in the Company at a price of £0.0425, pursuant to an orderly market agreement to satisfy market demand.

As announced on 29 March 2018, the Directors agreed to make available their allocated options for sale through Peterhouse should there be sufficient demand in the market following Admission. Mark Blower has today exercised 1,000,000 Options at a price of 0.5p per share and Noel Lyons has exercised 500,000 Options at a price of 0.5p per share.

No fees of any nature are payable to Peterhouse in respect of the orderly market arrangements.

Following the exercise of 1,500,000 Options in total, referred to above, the Company has 424,400,000 Ordinary Shares in issue. The total number of Ordinary Shares with voting rights is now 424,400,000 Ordinary Shares.

The Directors of the Company accept responsibility for the contents of this announcement.

For further information please contact:


Geremy Thomas
Founder & CEO
Sativa Investments PLC
+44 (0) 20 7971 1255


NEX Exchange Corporate Adviser
Guy Miller
Peterhouse Capital Limited
+44 (0) 20 7469 0930


Financial PR and IR
Julian Bosdet / Dylan Mark /
Alejandra Campuzano
Abchurch Communications
+44 (0) 20 7469 4630

Mark Blower
Executive Director
Sativa Investments PLC
+44 (0) 20 7971 1255

Notes to Editors

Sativa will look for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector and the Company’s investment strategy will focus on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily accepted, with an initial focus on Canada.  The Company has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

The Company’s equity interest in a proposed investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa intends to acquire can either be public or private. 

The Company’s Board and Medical Cannabis Advisory Board have a combined 60 years’ industry experience with strong and extensive contacts in the industry, with significant pharmaceutical strength and experience.  Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: https://sativainvestments.co.uk/

(0 votes. Average 0 of 5)
Leave a reply

Your email address will not be published. Required fields are marked *